JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (1): 33-36.doi: 10.6040/j.issn.1671-7554.0.2013.505

• Articles • Previous Articles     Next Articles

Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3

 DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1   

  1. 1. Department of Chemotherapy, Cancer Center, Qilu Hospital of Shandong University, Jinan 250012,             China;
    2. School of Medicine, Zhejiang University, Hangzhou 310058, China
  • Received:2013-08-14 Online:2014-01-10 Published:2014-01-10

PDF (PC)

435

Abstract:

Objective  To explore the effect of PARP inhibitor AG014699 combined with  Gemcitabine or Docetaxel on the proliferation of androgen-independent prostate cancer cell line PC3. Methods  PC3 cells were cultured in vitro and then divided into PARP inhibitor group, Gemcitabine group, Docetaxel group, combination of PARP inhibitor and Gemcitabine group, combination of PARP inhibitor and Docetaxel group. CCK-8 method was used to assess the vitality of PC3 cells after different treatments; flow cytometry was adopted to determine apoptosis and distribution of cell cycle after PC3 cells were treated with PARP inhibitor. Results  PARP inhibitor AG014699 showed significant anti-proliferative effects on PC3 cells in a dose-and-time dependent pattern (P<0.05); Gemcitabine or Docetaxel inhibited the growth of PC3 cells in a dose dependent manner (P<0.05); compared with Gemcitabine or Docetaxel used alone, combination of PARP inhibitor and Gemcitabine or Docetaxel could significantly inhibit the growth of PC3 cells (P<0.05). Conclusion  PARP inhibitor AG014699 combined with Gemcitabine or Docetaxel has a synergistic antitumor effect on androgen-independent prostate cancer cell line PC3, which may become a promising therapy for androgen-independent prostate cancer.  

Key words: Androgen-independent prostate cancer, Gemcitabine, PC3 cells, PARP inhibitor, Docetaxel

[1] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[2] YIN Lei, YIN Rui, LI Wenjia, LIU Shuai, L(¨overU)Jiaju. CYLD improves bladder cancer gemcitabine chemosensitivity via suppressing autophagy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(8): 1-6.
[3] CUI Yong, ZHANG Rongxiang, WANG Fuli, WANG Guoying, FENG Jianlin, ZHANG Haixia. Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 53-57.
[4] SUN Jie, MU Xiaoyan, DONG Xueli. Combinational and sequential effect of sunitinib and gemcitabine on K-RAS mutant A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 45-49.
[5] ZHANG Miaoci, LI Ping, HA Minwin. Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 55-59.
[6] ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, LIU Li. Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 95-98.
[7] LI Xian-zhe1, SI Man-fei1,2, GUO Yan-xia1, YUAN Hui-qing1 . Differential expression and regulation of PDLIM4 in prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 34-39.
[8] WANG Hai-bin, MA Wei-ming, XIAO Pan, MA Tian-jia, ZHANG Huai-qiang. Differential  expressions of HSP60 in docetaxel treatment on
advanced hormone-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(8): 46-50.
[9] ZHENG Gui-xi, WANG Chuan-xin, ZHANG Xin, LI Wei, DU Lu-tao, LI Juan, LIU Hui. Screening and biological characteristics study of human
single chain Fv antibody against prostatic cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(11): 34-38.
[10] ZHANG Qun-cheng, MA Han-chen, SHAO Yang, ZHANG Dong, JIANG Shu-juan. Effects of trichostatin A and docetaxel on apoptosis and  α-tubulin in lung adenocarcinoma A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(6): 84-88.
[11] YANG Ning, HAN Jun-qing, SHENG Wei. Relationship of expressions of RRM1 and ERCC1 proteins with  response and prognosis in advanced NSCLC patients receiving  cisplatin combined with gemcitabine chemotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(6): 89-93.
[12] YU Ke-wei1,2, LIU Zhi-hong1, ZHANG Na1. Docetaxel-loaded Pluronic F68 polymeric micelles:preparation and in vitro evaluation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 156-160.
[13] . Docetaxel in combination with FHIT in treatment of human gastric cancer cells: an experimental study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(8): 29-32.
[14] JIA Zheng-fei,FENG Yong, ZHONG Qin,XIA Xiao-tian. Concurrent chemoradiotherapy with docetaxel/cisplatin for local advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(9): 898-900.
[15] LI Hong-mei,LI Hai-xia,LIU Kei-wei,WANG Xiu-mei. Three chemotherapy regimens including cisplatin for advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(5): 499-502.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd